Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy
Luca Scafuri(CTO Andrea Alesini), Giuseppe Di Lorenzo(CTO Andrea Alesini), Francesco Sabbatino(University of Salerno), Carlo Buonerba(CTO Andrea Alesini), Luigi Liguori(University of Naples Federico II), Grazia Arpino(University of Naples Federico II), Dario Trapani(Harvard University), Marco Cascella(University of Salerno), Anna Diana(University of Campania "Luigi Vanvitelli"), Mario Giuliano(Regione Campania), Paolo Tarantino(Harvard University), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonella Sciarra(University of Campania "Luigi Vanvitelli"), Vincenzo Tortora, Antonio Marra(European Institute of Oncology), Giuseppe Curigliano(European Institute of Oncology)
Cited by 0
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k